MedTrace Logo

H-1337 Ophthalmic Solution Phase 1/2

NCT03452033 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2022-07-12

Study results available
· View outcomes & findings →

Summary

The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with elevated intraocular pressure (IOP).

Conditions

  • Glaucoma, Open-Angle

Interventions

DRUG

H-1337 Placebo

H-1337 Placebo Vehicle

DRUG

H-1337 [1]

H-1337 Ophthalmic Solution Concentration 1

DRUG

H-1337 [2]

H-1337 Ophthalmic Solution Concentration 2

DRUG

H-1337 [3]

H-1337 Ophthalmic Solution Concentration 3

Sponsors & Collaborators

  • Allysta Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-15
Primary Completion
2018-08-15
Completion
2018-08-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03452033 on ClinicalTrials.gov